Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioblastoma 17Glioma 16Breast Neoplasms 14Prostatic Neoplasms 13Neoplasms 13Brain Neoplasms 11Pancreatic Neoplasms 10Colorectal Neoplasms 10Neoplasm Metastasis 9Multiple Myeloma 9Melanoma 8Lymphoma, B-Cell 8Lymphoma 8Recurrence 7Sarcoma 6Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Skin Neoplasms 4Lung Neoplasms 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Solid Tumor 3Pituitary Neoplasms 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Endometrial Serous Adenocarcinoma × 90 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡